PharmAbcine signs a CMO contract with Binex for Olinvacimab production


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ PharmAbcine signs a CMO contract with Binex for Olinvacimab production
Binex will produce olinvacimab at its new 5,000L production line

PharmAbcine, a biotech company focusing on the development of antibody therapeutics, announced on August 31 that it had signed a contract manufacturing organization(CMO) agreement with Binex, a leading biologics CDMO(Contract Development and Manufacturing Organization) company in Korea.

With the new contract, Binex will produce Olinvacimab (TTAC-0001), PharmAbcine's leading antibody therapeutics pipeline in oncology, using the new 5,000L production line while it was previously produced in the 1,000L production line. This contract will allow Binex to start the operation of its new 5,000L production line designed for large-scale commercial production.

As for PharmAbcine, this agreement will accommodate more timely and less costly delivery of Olinvacimab for its rapidly expanding list of both clinical and non-clinical studies. The list of studies includes, among others, the global clinical trial for Avastin refractory rGBM(recurrent glioblastoma multiforme) patients, the global combination trial with pembrolizumab for mTNBC(metastatic triple negative breast cancer), the research collaboration with SLBio in China for non-small cell lung cancer therapeutics, multiple investigator-initiated studies planned for solid tumors, etc.

"We are very pleased with this agreement as Binex has been a very reliable clinical manufacturing partner since the very beginning of the clinical trials," said Dr. Jin-San Yoo, CEO of PharmAbcine. "This agreement bodes well with our business strategy of aggressively expanding the indications of our front runner molecule."

About Binex

Binex (053030, KQ) is a biologics contract development and manufacturing organization located in South Korea. It has provided full range services from cell line development to GMP manufacturing for both the drug substance and drug product. CDMO services offered by Binex covers sophisticated analytic services and cGMP manufacturing for IMPs and commercial products (mAb/recombinant protein), leading to successful approval for INDs and BLAs of clients' project. Binex' CDMO capability has already been acknowledged not only by regulatory authorities in advanced countries but also by top pharmaceutical companies who want to in-license and commercialize biologics pipeline manufactured by Binex. 

About PharmAbcine Inc.

PharmAbcine is a clinical-stage biotech company focusing on the development of fully human antibody therapeutics to treat neovascular disorders, tumors, and other medically unmet diseases. It provides therapeutic antibodies for a wide spectrum of indications from oncology, immuno-oncology, ophthalmology, respiratory, to renal pathology.

PharmAbcine's leading pipeline, olinvacimab, an anti-VEGFR2 neutralizing fully human IgG, is currently in a phase II study for bevacizumab-nonresponding rGBM (recurrent glioblastoma multiforme) patients in both US and Australia. In collaboration with MERCK, olinvacimab plus pembrolizumab Phase Ib trials for mTNBC and rGBM are on-going.

PharmAbcine has its own HuPhage library and innovative selection system. PharmAbcine's advanced 3G expression system accommodates high levels of antibody production with high reproducibility. With its highly advanced technology platforms, it provides high-quality antibody generation services. The high standards have allowed PharmAbcine to expand co-development opportunities with not only existing but also potential partners.

Tags : #Olinvacimab #Binex #Pharmabcine #LatestPharmaCMONewsSep3 #LatestPharmaNewsUpdates #NonSmallCellLungCancer

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026